<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01220544</url>
  </required_header>
  <id_info>
    <org_study_id>BELEHAPLO-1412001</org_study_id>
    <nct_id>NCT01220544</nct_id>
  </id_info>
  <brief_title>Haploidentical Transplantation With Early Adoptive Transfer of CD56+CD3- NK Cells</brief_title>
  <official_title>Transplantation of Hematopoetic Stem Cells and Infusion of CD56+CD3- NK Cells From Haploidentical Donors for Patients With Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Experimental and clinical data suggest that alloreactive NK cells can reduce the risk of
      graft-rejection, GvHD and leukemic relapse after HLA-mismatched transplantation. The
      effectiveness of allogeneic NK cells is a function of HLA-differences between donor and
      recipient that give rise to NK cell clones which do not express inhibitory receptors matching
      for the HLA molecules of the recipient. Aim of the study is to evaluate cellular therapy with
      alloreactive, IL-2 activated NK cells after transplantation of T-cell depleted stem cell
      grafts from one haplotype mismatched family donors in patients with hematological
      malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2001</start_date>
  <completion_date type="Anticipated">October 2011</completion_date>
  <primary_completion_date type="Anticipated">October 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate feasibility and safety of alloreactive CD56+/CD3- donor NK cells after one haplotype mismatched transplantation</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate feasibility and safety of cellular immunotherapy with purified alloreactive CD56+/CD3- donor NK cells after one haplotype mismatched hematopoietic stem cell transplantation in patients with high risk hematological malignancies who lack an HLA-identical donor.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>transplant related mortality</measure>
    <time_frame>1 year</time_frame>
    <description>The investigation of transplant related mortality (incidence of veno occlusive disease; incidence and type of infectious complications).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effectiveness</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate the effectiveness of the therapy (relapse rate; disease free survival; MRD monitoring).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>technical aspects of the cell separation procedure</measure>
    <time_frame>7 days</time_frame>
    <description>To investigate technical aspects of the cell separation procedure (problems of stem cell mobilization; yield, viability, sterility and purity of the CD34+ and CD56+CD3- cell fraction; log CD3 depletion; in vitro anti-leukemic activity of the CD56+CD3- cell fraction).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stable engraftment of haploidentical stem cell grafts can be achieved after conditioning with total body irradiation, thiotepa, fludarabine and OKT3 and subsequent transfer of megadoses of positively selected CD34+ stem cells and CD56+CD3- NK-cells.</measure>
    <time_frame>28 days</time_frame>
    <description>Graft rejection is defined as neutrophils &lt; 0.5 x 10e9/l on day+28 post transplantation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acute Myeloid Leukemias</condition>
  <condition>Advanced Hematological Malignancies</condition>
  <condition>Indication for Allogeneic Stem Cell Transplantation</condition>
  <condition>no HLA-identical Donor Available</condition>
  <arm_group>
    <arm_group_label>HaploTransplant with NK cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Haploidentical transplantation of mega-dose CD34+ hematopoetic stem cells with transfer of CD56+CD3-NK cells at day +2</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Haploidentical transplantation with donor NK cells</intervention_name>
    <description>Pat received a myeloablative conditioning regimen with 12 Gy total-body irradiation in six single doses from day -11 to day -9, thiotepa (5mg/kg/d) on days -8 and -7, fludarabine (40mg/m2/d) from day -6 to day -3, and OKT-3 (5mg/d) from day -5 to day +3. The stem cell graft was aimed to contain &gt; 8 x 10e6 CD34+ cells/kg and &lt; 5 x 10e4 CD3+ cells/kg. A minimum of 1 x 10e7 CD56+CD3- NK cells/kg will be transferred on days +2.</description>
    <arm_group_label>HaploTransplant with NK cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with AML or ALL in first CR with the following high risk features:

               1. AML with aberration Del (5q) -5, del (7q) -7, t(9;22) or t(6;9), abn 3q, 9q, 11q,
                  20q, 21q, 17p;

               2. AML with a complex caryotype;

               3. secondary AML after previous chemo- or radiotherapy or MDS;

               4. Ph-positive ALL

          -  Patients with AML or ALL after induction failure or in second CR

          -  Patients with CML in second chronic or accelerated phase

          -  Patients with malignant Lymphoma and the following high risk features:

               1. relapse after autologous transplantation

               2. primary chemotherapy refractory disease

          -  All patients must fulfill the following criteria:

               1. lack of a suitable HLA-identical family, unrelated or cord blood donor

               2. no active infection, no severe impairment of cardial, pulmonary, renal and
                  hepatic function

               3. blast count in the marrow &lt; 30%

               4. informed consent

        Exclusion Criteria:

          -  active infection, no severe impairment of cardial, pulmonary, renal and hepatic
             function

          -  blast count in the marrow &gt; 30%

          -  unable or unwilling to sign and/or understand informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>54 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lutz Uharel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dietger Niederwieser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Leipzig</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lutz Uharek, MD</last_name>
    <phone>+49308445</phone>
    <phone_ext>4550</phone_ext>
    <email>lutz.uharek@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Birte Friedrichs, MD</last_name>
    <phone>+49308445</phone>
    <phone_ext>4574</phone_ext>
    <email>birte.friedrichs@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charite Campus Benjamin FRanklin, Medical Clinic III, Department of Hematology/Oncology</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lutz Uharek, Prof.</last_name>
      <phone>+49308445</phone>
      <phone_ext>4550</phone_ext>
      <email>lutz.uharek@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Birte Friedrichs, Dr.</last_name>
      <phone>+49308445</phone>
      <phone_ext>4574</phone_ext>
      <email>birte.friedrichs@charite.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medical Clinic II, Department of Hematology/Oncology, University of Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dietger Niederwieser, Prof.</last_name>
      <phone>+4934197</phone>
      <phone_ext>13050</phone_ext>
      <email>dietger@medizin.uni-leipzig.de</email>
    </contact>
    <contact_backup>
      <last_name>Nadezda Basara, Dr.</last_name>
      <email>Nadezda.Basara@medizin.uni-leipzig.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2010</study_first_submitted>
  <study_first_submitted_qc>October 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2010</study_first_posted>
  <last_update_submitted>October 13, 2010</last_update_submitted>
  <last_update_submitted_qc>October 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Lutz Uharek</name_title>
    <organization>Charite University Medicine</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

